Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E141.69 EPS (ttm)0.19 Insider Own1.10% Shs Outstand293.24M Perf Week-1.51%
Market Cap7.85B Forward P/E43.76 EPS next Y0.61 Insider Trans-27.26% Shs Float276.47M Perf Month2.41%
Income58.20M PEG3.08 EPS next Q0.07 Inst Own82.00% Short Float5.75% Perf Quarter34.84%
Sales319.70M P/S24.56 EPS this Y63.70% Inst Trans0.07% Short Ratio3.73 Perf Half Y21.18%
Book/sh0.51 P/B52.51 EPS next Y139.06% ROA10.40% Target Price29.83 Perf Year154.32%
Cash/sh1.19 P/C22.49 EPS next 5Y46.00% ROE59.70% 52W Range10.04 - 28.45 Perf YTD79.61%
Dividend- P/FCF53.53 EPS past 5Y-19.90% ROI-15.10% 52W High-5.87% Beta1.99
Dividend %- Quick Ratio4.10 Sales past 5Y-7.90% Gross Margin96.70% 52W Low166.73% ATR0.97
Employees287 Current Ratio4.10 Sales Q/Q172.70% Oper. Margin22.90% RSI (14)55.76 Volatility3.01% 3.72%
OptionableYes Debt/Eq0.00 EPS Q/Q137.30% Profit Margin18.20% Rel Volume0.73 Prev Close26.91
ShortableYes LT Debt/Eq0.00 EarningsAug 02 AMC Payout0.00% Avg Volume4.27M Price26.78
Recom2.10 SMA20-0.73% SMA508.41% SMA20030.72% Volume3,126,020 Change-0.48%
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-16-17 09:45AM  Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis TheStreet.com
08:00AM  Today's Research Reports on Trending Tickers: Exelixis Inc. and Sarepta Therapeutics Inc. ACCESSWIRE
07:00AM  Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer Business Wire
Aug-15-17 04:22PM  Why Gilead Sciences Might Not Make an Oncology Acquisition Motley Fool
Aug-14-17 01:06PM  What Amgens Analysts Recommend in August 2017 Market Realist
08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-13-17 03:26AM  Edited Transcript of EXEL earnings conference call or presentation 2-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:02AM  IHS Markit Score upgrades Exelixis Inc to 72 out of 100, despite ranking positively in only one IHS Markit category. Markit
Aug-09-17 11:18AM  Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts Motley Fool
Aug-04-17 04:35PM  Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass Zacks
02:50PM  Exelixis, Inc. Grows Revenue, Eyes Treating More Patients Motley Fool
10:12AM  Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag Zacks
Aug-03-17 04:41PM  Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates Zacks
04:21PM  Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales Zacks
03:41PM  3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance Motley Fool
02:41PM  The Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom Benzinga
11:33AM  Dynavax Technologies Corporation (DVAX) Has the Market Buzzing with Heplisav Approval at the Finish Line, Exelixis, Inc. (EXEL) Refractory RCC Drug Going Strong in its Launch SmarterAnalyst
01:07AM  Exelixis tops Street 2Q forecasts Associated Press
Aug-02-17 04:05PM  Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update Business Wire
12:20PM  Investor Network: Exelixis, Inc. to Host Earnings Call ACCESSWIRE
10:24AM  Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised Zacks
Aug-01-17 10:46AM  Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2 Zacks
08:00AM  Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress Business Wire
Jul-31-17 01:56PM  ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up Zacks
10:44AM  Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise Zacks
Jul-28-17 02:33PM  Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line Zacks
Jul-27-17 12:04PM  Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View Zacks
11:27AM  GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance Zacks
08:00AM  Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up Zacks
Jul-25-17 04:25PM  Three biotech companies to watch ahead of earnings MarketWatch
Jul-24-17 10:44AM  What's in the Cards for Exelixis (EXEL) in Q2 Earnings? Zacks
Jul-21-17 02:42PM  2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't Motley Fool
12:57PM  William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL) SmarterAnalyst
Jul-20-17 06:19PM  Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab Zacks
07:00AM  Exelixis Announces Settlement of Dispute with Genentech Regarding Companies Collaboration Agreement for Cobimetinib Business Wire
Jul-19-17 10:16AM  Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt Zacks
08:15AM  Agenus (AGEN) Catches Eye: Stock Moves Up 8.7% in Session Zacks
Jul-17-17 06:49PM  Cramer's lightning round: This business is better than people think CNBC
04:05PM  Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017 Business Wire
03:11PM  Arena Announces Secondary Stock Worth $150M (revised) Zacks
Jul-13-17 06:11PM  Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017? Zacks
06:03PM  BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug Zacks
08:50AM  Why Exelixis (EXEL) Could Be an Impressive Growth Stock Zacks
Jul-12-17 10:13AM  Arena Announces Secondary Stock Offering of 150M Shares Zacks
Jul-11-17 05:08PM  Five Scorching Hot Stocks Screaming Higher Zacks
04:44PM  Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx Zacks
Jul-10-17 09:40AM  Biotech Movers: Exelixis, Omeros, Inovio TheStreet.com
08:00AM  Today's Research Reports on Stocks to Watch: RXi Pharmaceuticals Corporation and Exelixis Inc. Accesswire
08:00AM  Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Business Wire
Jul-07-17 09:05AM  This Biotech Finds Its Stride With Kidney Cancer Treatment Investor's Business Daily
08:24AM  The Cabosun Shone on Exelixis in June, Sending Its Shares Up 32% Motley Fool
Jul-05-17 04:12PM  These 6 Biotech, Drug Plays Are In Buy Range: Investing Action Plan Investor's Business Daily
11:44AM  3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates Motley Fool
09:54AM  These 6 Biotech, Drug Plays Are In Buy Range: Investing Action Plan Investor's Business Daily
09:30AM  The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners Zacks
Jul-03-17 02:43PM  Top Analyst Reports for Disney, Charter Communications & Monsanto Zacks
11:43AM  Best Stocks For The Second Half of 2017 Zacks
Jun-29-17 08:00AM  Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of Indebtedness Business Wire
Jun-27-17 10:28AM  Top Ranked Momentum Stocks to Buy for June 27th Zacks -5.26%
08:00AM  Today's Research Reports on Trending Tickers: Exelixis and Seattle Genetics Accesswire
Jun-26-17 04:20PM  Biotech Rally Gets Second Wind As This Small Cap Nears Breaks Out Investor's Business Daily
04:17PM  Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone Investor's Business Daily
11:32AM  This Drugmaker Flirts With Breakout As Some Biotechs Rally Investor's Business Daily
06:00AM  The Reason for the Big Rise in Biotech Stocks Investopedia
Jun-25-17 09:42AM  These 3 Stocks Are Up Over 500% in the Last 3 Years Motley Fool
Jun-24-17 06:42AM  Better Buy: Exelixis, Inc. vs. Novartis AG Motley Fool
Jun-23-17 12:06PM  Roundtable: 1 Stock I Brag About Owning Motley Fool
Jun-22-17 04:55PM  Exelixis, Inc. Value Analysis (NASDAQ:EXEL) : June 22, 2017 Capital Cube
04:27PM  After Celgene, Regeneron Breakouts, This Biotech Stock May Be Next Investor's Business Daily
02:50AM  Biotech Exelixis May Break Out On Cancer Drug Trial Results Investor's Business Daily
Jun-21-17 02:58PM  Two Bullish Biotech Stocks And A Very Bearish Looking Yelp Forbes +7.81%
10:57AM  AVEO Reaches Enrollment Target in Pivotal Tivozanib Study Zacks
Jun-20-17 05:35PM  Exelixis's Cabometyx Positive for First-Line Kidney Cancer Zacks
08:27AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : June 20, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: Exelixis and Westport Fuel Systems Accesswire
Jun-19-17 05:21PM  Why Exelixis, Inc. Zoomed Higher Today Motley Fool +12.15%
08:00AM  Exelixis Announces Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Business Wire
Jun-14-17 09:34AM  Key Takeaways From William Blairs Annual Growth Stock Conference: Gilead Sciences, Inc. (GILD), Exelixis, Inc. (EXEL) SmarterAnalyst
Jun-13-17 05:32PM  Exelixis Initiates Cabozantinib-Tecentriq Combination Trial Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Exelixis and Opko Health Accesswire
Jun-12-17 08:05AM  Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors Business Wire
Jun-08-17 04:05PM  Exelixis to Present at the William Blair & Co. 37th Annual Growth Stock Conference on June 13 Business Wire
Jun-06-17 08:09AM  2 Reasons Exelixis, Inc. Shares Sank 16% in May Motley Fool
Jun-05-17 04:29PM  3 Stocks With Exelixis-Like Return Potential Motley Fool
01:48PM  Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data Benzinga
Jun-01-17 09:27AM  Why Is Exelixis (EXEL) Down 20.9% Since the Last Earnings Report? Zacks
May-26-17 01:07PM  ETFs with exposure to Exelixis, Inc. : May 26, 2017 Capital Cube
09:33AM  Biotech Movers: Immunomedics, Aerie, Exelixis TheStreet.com
May-25-17 01:05PM  3 Stocks That Tripled in a Single Year Motley Fool
May-19-17 08:00AM  Top 5 Biotech Stocks for 2017 Investopedia -6.42%
May-18-17 08:00AM  Today's Research Reports on Biotech Stocks to Watch: Exelixis and Amicus Therapeutics Accesswire +5.89%
May-15-17 03:41PM  ETFs with exposure to Exelixis, Inc. : May 15, 2017 Capital Cube
May-10-17 09:31PM  Edited Transcript of EXEL earnings conference call or presentation 1-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-09-17 08:59AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : May 9, 2017 Capital Cube
May-04-17 03:56PM  ETFs with exposure to Exelixis, Inc. : May 4, 2017 Capital Cube
09:08AM  3 Biotech Stocks Projected to Grow Their EPS by at Least 415% in 2018 Motley Fool
May-03-17 04:05PM  Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
12:45PM  Will Exelixis Break Out from Key Resistance? Investopedia
10:43AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 Capital Cube
09:30AM  Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy Zacks
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haley Patrick J.Sr. Vice President, CommercialMay 30Sale18.465,00092,300102,193Jun 01 07:09 PM
FELDBAUM CARL BDirectorMay 15Option Exercise8.7519,000166,19067,721May 16 09:13 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 15Option Exercise5.0412,50163,005183,005May 16 09:12 PM
FELDBAUM CARL BDirectorMay 15Sale21.5832,988711,83134,733May 16 09:13 PM
MORRISSEY MICHAELPresident and CEOMay 10Option Exercise1.86100,000185,910160,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 10Sale22.07100,0002,207,00060,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Option Exercise1.90100,000190,000111,214May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Sale21.69100,0002,168,70660,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Option Exercise1.9011,30021,47071,300May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Sale21.8111,300246,45360,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 05Option Exercise1.90100,000190,000149,555May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 05Sale21.85100,0002,184,70260,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Option Exercise1.9059,149112,383119,149May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Sale22.1759,1491,311,33360,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Option Exercise1.90100,000190,000129,427May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Sale22.67100,0002,266,80360,000May 05 06:53 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Option Exercise9.9189,910891,008260,414May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Sale23.0189,9102,068,519170,504May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOApr 17Option Exercise9.9110,09099,992168,143Apr 18 07:57 PM
MARCHESI VINCENT TDirectorApr 03Option Exercise10.5310,000105,300130,070Apr 04 08:00 PM
MARCHESI VINCENT TDirectorApr 03Sale21.3010,000213,000120,070Apr 04 08:00 PM
WYSZOMIERSKI JACK LDirectorMar 31Option Exercise10.5310,000105,30078,110Mar 31 06:35 PM
WYSZOMIERSKI JACK LDirectorMar 31Sale21.575,150111,08672,960Mar 31 06:35 PM
COHEN CHARLESDirectorMar 27Option Exercise10.5310,000105,300248,180Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 27Sale21.026,884144,702267,946Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 22Option Exercise1.7055,00093,500301,617Mar 24 07:41 PM
Hessekiel JeffreyEVP and General CounselMar 22Sale20.5423,787488,585277,830Mar 24 07:41 PM
PAPADOPOULOS STELIOSDirectorMar 20Option Exercise10.5310,000105,3001,238,471Mar 21 07:28 PM
FELDBAUM CARL BDirectorMar 20Option Exercise10.5310,000105,30058,721Mar 21 07:29 PM
PAPADOPOULOS STELIOSDirectorMar 20Sale21.6610,000216,6001,228,471Mar 21 07:28 PM
FELDBAUM CARL BDirectorMar 20Sale21.7710,000217,70048,721Mar 21 07:29 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Option Exercise6.2050,007310,179208,060Mar 17 07:51 PM
WILLSEY LANCEDirectorMar 15Option Exercise10.5310,000105,300578,273Mar 17 07:52 PM
WILLSEY LANCEDirectorMar 15Sale22.8610,000228,600568,273Mar 17 07:52 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Sale22.5350,0071,126,658158,053Mar 17 07:51 PM
COHEN CHARLESDirectorMar 13Sale21.8210,000218,200238,180Mar 14 08:12 PM
MARCHESI VINCENT TDirectorMar 10Option Exercise3.1340,000125,200160,070Mar 10 07:37 PM
MARCHESI VINCENT TDirectorMar 10Sale21.9840,000879,200120,070Mar 10 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 06Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 06Sale22.61100,0002,261,00060,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Option Exercise7.27100,000727,000346,617Mar 07 08:00 PM
MORRISSEY MICHAELPresident and CEOMar 03Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
Senner Christopher J.EVP and CFOMar 03Sale22.8011,000250,800100,398Mar 03 08:20 PM
Haley Patrick J.Sr. Vice President, CommercialMar 03Sale23.042,50057,600107,193Mar 07 07:45 PM
MORRISSEY MICHAELPresident and CEOMar 03Sale22.83100,0002,283,00060,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Sale23.04100,0002,303,678246,617Mar 07 08:00 PM
POSTE GEORGEDirectorMar 02Option Exercise4.5167,400303,660144,955Mar 03 08:17 PM
POSTE GEORGEDirectorMar 02Sale22.5867,4001,521,89277,555Mar 03 08:17 PM
POSTE GEORGEDirectorMar 01Option Exercise10.538,85093,19186,405Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise7.3645,000331,350118,600Mar 03 08:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1945,000998,55073,600Mar 03 08:18 PM
POSTE GEORGEDirectorMar 01Sale22.188,850196,29377,555Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise6.9270,000484,300143,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale18.6570,0001,305,50073,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Option Exercise5.7470,000401,800143,600Jan 05 08:25 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Sale14.6570,0001,025,63673,600Jan 05 08:25 PM
FELDBAUM CARL BDirectorDec 16Option Exercise10.4125,000260,25073,721Dec 16 07:29 PM
FELDBAUM CARL BDirectorDec 16Sale17.0325,000425,75048,721Dec 16 07:29 PM
Garber Alan MDirectorDec 09Option Exercise10.5310,000105,30069,161Dec 09 08:02 PM
Garber Alan MDirectorDec 09Sale16.907,832132,36161,329Dec 09 08:02 PM
SCANGOS GEORGE ADirectorDec 07Option Exercise8.993563,2001,463,824Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 07Sale17.901763,1501,463,648Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Option Exercise8.99357,9763,218,2041,668,186Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Sale17.81204,7183,646,0281,463,468Dec 07 07:03 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Option Exercise5.2770,000368,800143,600Dec 02 07:14 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Option Exercise8.9922,000197,780180,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Sale16.6670,0001,166,20073,600Dec 02 07:14 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Sale16.7322,000368,060158,053Dec 02 07:13 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Option Exercise8.9922,000197,780180,053Nov 14 07:36 PM
MORRISSEY MICHAELPresident and CEONov 09Option Exercise8.99200,0001,798,000260,000Nov 14 07:37 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Option Exercise5.1770,000362,000143,600Nov 14 07:34 PM
MORRISSEY MICHAELPresident and CEONov 09Sale15.00200,0003,000,00060,000Nov 14 07:37 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Sale15.0022,000330,000158,053Nov 14 07:36 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Sale13.1570,000920,50073,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Option Exercise9.73132,6621,290,801267,596Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Sale10.98131,1551,440,082136,441Sep 02 04:34 PM